Connection

Paolo Maggi to Rilpivirine

This is a "connection" page, showing publications Paolo Maggi has written about Rilpivirine.
Connection Strength

0.181
  1. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
    View in: PubMed
    Score: 0.181
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.